Literature DB >> 12531332

Virus-like particle and DNA-based candidate AIDS vaccines.

Qizhi Yao1, Zhigao Bu, Andrei Vzorov, Chinglai Yang, Richard W Compans.   

Abstract

Both humoral and cellular immune responses are critical for the control of HIV infection and replication. We have established systems for production of HIV and SIV virus-like particles containing high levels of viral Env proteins using the baculovirus expression system. Evaluation of immunogenicity showed that immunization with virus-like particles induced both cellular and neutralizing antibody responses. Furthermore, mucosal administration of virus-like particles effectively induced both mucosal and systemic immune responses. These results indicate that virus-like particles consisting of HIV structural proteins are an attractive vaccine platform for eliciting anti-viral immune responses, especially neutralizing antibody responses. We have also synthesized codon-optimized genes for HIV Env proteins and evaluated their immunogenicity. Combinations of virus-like particle and DNA-based vaccination are promising for inducing strong cellular and neutralizing antibody responses against HIV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531332     DOI: 10.1016/s0264-410x(02)00572-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.

Authors:  Bao-Zhong Wang; Weimin Liu; Sang-Moo Kang; Munir Alam; Chunzi Huang; Ling Ye; Yuliang Sun; Yingying Li; Denise L Kothe; Peter Pushko; Terje Dokland; Barton F Haynes; Gale Smith; Beatrice H Hahn; Richard W Compans
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.

Authors:  Lifei Yang; Yufeng Song; Xiaomin Li; Xiaoxing Huang; Jingjing Liu; Heng Ding; Ping Zhu; Paul Zhou
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

Review 3.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

4.  Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP.

Authors:  Daphne Nikles; Patricia Bach; Klaus Boller; Christoph A Merten; Fabio Montrasio; Frank L Heppner; Adriano Aguzzi; Klaus Cichutek; Ulrich Kalinke; Christian J Buchholz
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines.

Authors:  Vinod Kumar Bhaskara Pillai; Sunil Kannanganat; Pablo Penaloza-Macmaster; Lakshmi Chennareddi; Harriet L Robinson; Jerry Blackwell; Rama Rao Amara
Journal:  Vaccine       Date:  2011-06-07       Impact factor: 3.641

6.  Protection against lethal challenge by Ebola virus-like particles produced in insect cells.

Authors:  Yuliang Sun; Ricardo Carrion; Ling Ye; Zhiyuan Wen; Young-Tae Ro; Kathleen Brasky; Anysha E Ticer; E Ellen Schwegler; Jean L Patterson; Richard W Compans; Chinglai Yang
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

7.  Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses.

Authors:  Ling Ye; Zhiyuan Wen; Ke Dong; Lei Pan; Zhigao Bu; Richard W Compans; Huizhong Zhang; Chinglai Yang
Journal:  J Biomed Biotechnol       Date:  2010-05-25

8.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

9.  Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.

Authors:  Lucy A Perrone; Attiya Ahmad; Vic Veguilla; Xiuhua Lu; Gale Smith; Jacqueline M Katz; Peter Pushko; Terrence M Tumpey
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

10.  Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.

Authors:  Yossef Raviv; Robert Blumenthal; S Mark Tompkins; Jennifer Humberd; Robert J Hogan; Mathias Viard
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.